title: Vaccine protection against a heterologous, non-syncytium-inducing, primary human immunodeficiency virus.
abstract: Vaccine-induced protection of chimpanzees against laboratory-adapted and syncytium-inducing, multiply passaged primary human immunodeficiency virus type 1 (HIV-1) isolates, but not against non-syncytium-inducing, minimally passaged ones, has been demonstrated. Following challenge with such an isolate, HIV-15016, we obtained complete protection in one of three chimpanzees previously protected against low- and high-dose HIV-1SF2 exposures after immunization with an adenovirus-HIV-1MN gp160 priming-HIV-1SF2 gp120 boosting regimen. At challenge, the protected chimpanzee exhibited broad humoral immunity, including neutralizing antibody activity. These results demonstrate the potential of this combination vaccine strategy and suggest that vaccine protection against an HIV isolate relevant to infection of people is feasible.
authors.affiliation: Basic Research Laboratory, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892-4255, USA. guroffm@dc37a.nci.nih.gov
authors.forename: M
authors.initials: M
authors.lastname: Robert-Guroff
authors.forename: H
authors.initials: H
authors.lastname: Kaur
authors.forename: L J
authors.initials: LJ
authors.lastname: Patterson
authors.forename: M
authors.initials: M
authors.lastname: Leno
authors.forename: A J
authors.initials: AJ
authors.lastname: Conley
authors.forename: P M
authors.initials: PM
authors.lastname: McKenna
authors.forename: P D
authors.initials: PD
authors.lastname: Markham
authors.forename: E
authors.initials: E
authors.lastname: Richardson
authors.forename: K
authors.initials: K
authors.lastname: Aldrich
authors.forename: K
authors.initials: K
authors.lastname: Arora
authors.forename: L
authors.initials: L
authors.lastname: Murty
authors.forename: L
authors.initials: L
authors.lastname: Carter
authors.forename: S
authors.initials: S
authors.lastname: Zolla-Pazner
authors.forename: F
authors.initials: F
authors.lastname: Sinangil
mesh_terms: D016915:AIDS Vaccines / Q000008:administration & dosage / Q000494:pharmacology*; D000256:Adenoviridae / Q000235:genetics / Q000276:immunology; D000595:Amino Acid Sequence; D000818:Animals; D017931:DNA Primers / Q000235:genetics; D015483:HIV Antibodies / Q000097:blood; D015699:HIV Envelope Protein gp120 / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology; D019302:HIV Envelope Protein gp160 / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology; D015658:HIV Infections / Q000276:immunology / Q000517:prevention & control / Q000821:virology; D015497:HIV-1 / Q000235:genetics / Q000276:immunology* / Q000472:pathogenicity*; D006801:Humans; D007117:Immunization, Secondary; D008969:Molecular Sequence Data; D009500:Neutralization Tests; D002679:Pan troglodytes; D010446:Peptide Fragments / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology; D012367:RNA, Viral / Q000235:genetics / Q000302:isolation & purification; D014776:Virus Cultivation
chemical_list: D016915:AIDS Vaccines; D017931:DNA Primers; D015483:HIV Antibodies; D015699:HIV Envelope Protein gp120; D019302:HIV Envelope Protein gp160; C059762:HIV envelope protein gp120 (305-321); D010446:Peptide Fragments; D012367:RNA, Viral